Fobos
Antifungal agent.
One capsule contains:
active substance – fluconazole 50 mg or 150 mg,
excipients: lactose monohydrate, corn starch, anhydrous colloidal silicon dioxide, magnesium stearate, sodium lauryl sulfate,
shell (for a dosage of 50 mg): gelatin, blue patented V (E131), quinoline yellow (E104), iron (III) oxide red (E172), titanium dioxide (E171), iron (III) oxide yellow (E172)
shell (for a dosage of 150 mg): gelatin, titanium dioxide (E171).
-cryptococcosis, including cryptococcal meningitis and infections of other localization (including lungs, skin), both in patients with a normal immune response and in patients with various forms of immunosuppression (including in AIDS patients, during organ transplantation ); the drug can be used to prevent cryptococcal infection in AIDS patients;
– generalized candidiasis, including candidemia, disseminated candidiasis and other forms of invasive candidiasis (including infections of the peritoneum, endocardium, eyes, respiratory and urinary tract). Treatment can be carried out in patients with malignant neoplasms, patients in intensive care units, patients receiving cytotoxic or immunosuppressive drugs, as well as in the presence of other factors predisposing to the development of candidiasis;
– candidiasis of the mucous membranes, incl. oral cavity and pharynx (including atrophic candidiasis of the oral cavity associated with wearing dentures), esophagus, non-invasive bronchopulmonary infections, candiduria, skin candidiasis; prevention of recurrence of oropharyngeal candidiasis in AIDS patients;
-genital candidiasis: vaginal candidiasis (acute and chronic recurrent), prophylactic use in order to reduce the frequency of relapses of vaginal candidiasis (3 or more episodes per year); candidal balanitis;
– prevention of fungal infections in patients with malignant neoplasms who are prone to such infections as a result of cytotoxic chemotherapy or radiation therapy;
– mycosis of the skin, including mycoses of the feet, body, groin, pityriasis versicolor, onychomycosis and skin candidal infections;
– deep endemic mycoses, coccidioidomycosis, paracoccidioidomycosis, sporotrichosis and histoplasmosis in patients with normal immunity.
Inside. Adults with cryptococcal infections, candidemia, disseminated candidiasis, other invasive candidiasis infections are prescribed 400 mg on day 1, then 200-400 mg once a day.
The duration of the course depends on the clinical and mycological reaction (with cryptococcal meningitis it is at least 6-8 weeks).
For the prevention of cryptococcal meningitis in AIDS patients, therapy at a dose of 200 mg per day can be continued for a long time.
With oropharyngeal candidiasis – 50-100 mg once a day for 7-10 days, in patients with suppressed immunity – treatment is longer (14 or more days).
With atrophic oral candidiasis associated with wearing dentures – 50 mg once a day for 14 days.
For other candidal infections of the mucous membranes – 50-100 mg per day, the duration of treatment is 14-30 days.
For the prevention of recurrence of oropharyngeal candidiasis in AIDS patients after completing a full course of primary therapy – 150 mg once a week.
With vaginal candidiasis – 150 mg once, by mouth. To reduce the frequency of relapses, 150 mg is used once a month.
For skin infections, including mycoses of the feet, groin skin and candidal infections – 150 mg once a week or 50 mg once a day, the duration of treatment is 2-4 weeks (up to 6 weeks).
With onychomycosis – 150 mg once a week; treatment continues until the infected nail changes.
With deep endemic mycoses – 200-400 mg per day, the duration of therapy is determined individually.
Children with mucosal candidiasis – 3 mg / kg per day, on the first day, a loading dose of 6 mg / kg can be prescribed.
In the treatment of generalized candidiasis and cryptococcal infection – 6-12 mg / kg per day.
For the prevention of fungal infections – 3-12 mg / kg per day.
In renal failure, a loading dose of 50-400 mg is initially administered; with CC more than 50 ml / min, the usual daily dose is prescribed, with CC 11-50 – 50% of the recommended dose or the usual dose every 2 days; patients on hemodialysis – 1 dose after each dialysis.
Composition
One capsule contains:
active substance – fluconazole 50 mg or 150 mg,
excipients: lactose monohydrate, corn starch, anhydrous colloidal silicon dioxide, magnesium stearate, sodium lauryl sulfate,
shell (for a dosage of 50 mg): gelatin, blue patented V (E131), quinoline yellow (E104), iron (III) oxide red (E172), titanium dioxide (E171), iron (III) oxide yellow (E172)
shell (for a dosage of 150 mg): gelatin, titanium dioxide (E171).
Indications for use
-cryptococcosis, including cryptococcal meningitis and infections of other localization (including lungs, skin), both in patients with a normal immune response and in patients with various forms of immunosuppression (including in AIDS patients, during organ transplantation ); the drug can be used to prevent cryptococcal infection in AIDS patients;
– generalized candidiasis, including candidemia, disseminated candidiasis and other forms of invasive candidiasis (including infections of the peritoneum, endocardium, eyes, respiratory and urinary tract). Treatment can be carried out in patients with malignant neoplasms, patients in intensive care units, patients receiving cytotoxic or immunosuppressive drugs, as well as in the presence of other factors predisposing to the development of candidiasis;
– candidiasis of the mucous membranes, incl. oral cavity and pharynx (including atrophic candidiasis of the oral cavity associated with wearing dentures), esophagus, non-invasive bronchopulmonary infections, candiduria, skin candidiasis; prevention of recurrence of oropharyngeal candidiasis in AIDS patients;
-genital candidiasis: vaginal candidiasis (acute and chronic recurrent), prophylactic use in order to reduce the frequency of relapses of vaginal candidiasis (3 or more episodes per year); candidal balanitis;
– prevention of fungal infections in patients with malignant neoplasms who are prone to such infections as a result of cytotoxic chemotherapy or radiation therapy;
– mycosis of the skin, including mycoses of the feet, body, groin, pityriasis versicolor, onychomycosis and skin candidal infections;
– deep endemic mycoses, coccidioidomycosis, paracoccidioidomycosis, sporotrichosis and histoplasmosis in patients with normal immunity.
Mode of application
Inside. Adults with cryptococcal infections, candidemia, disseminated candidiasis, other invasive candidiasis infections are prescribed 400 mg on day 1, then 200-400 mg once a day.
The duration of the course depends on the clinical and mycological reaction (with cryptococcal meningitis it is at least 6-8 weeks).
For the prevention of cryptococcal meningitis in AIDS patients, therapy at a dose of 200 mg per day can be continued for a long time.
With oropharyngeal candidiasis – 50-100 mg once a day for 7-10 days, in patients with suppressed immunity – treatment is longer (14 or more days).
With atrophic oral candidiasis associated with wearing dentures – 50 mg once a day for 14 days.
For other candidal infections of the mucous membranes – 50-100 mg per day, the duration of treatment is 14-30 days.
For the prevention of recurrence of oropharyngeal candidiasis in AIDS patients after completing a full course of primary therapy – 150 mg once a week.
With vaginal candidiasis – 150 mg once, by mouth. To reduce the frequency of relapses, 150 mg is used once a month.
For skin infections, including mycoses of the feet, groin skin and candidal infections – 150 mg once a week or 50 mg once a day, the duration of treatment is 2-4 weeks (up to 6 weeks).
With onychomycosis – 150 mg once a week; treatment continues until the infected nail changes.
With deep endemic mycoses – 200-400 mg per day, the duration of therapy is determined individually.
Children with mucosal candidiasis – 3 mg / kg per day, on the first day, a loading dose of 6 mg / kg can be prescribed.
In the treatment of generalized candidiasis and cryptococcal infection – 6-12 mg / kg per day.
For the prevention of fungal infections – 3-12 mg / kg per day.
In renal failure, a loading dose of 50-400 mg is initially administered; with CC more than 50 ml / min, the usual daily dose is prescribed, with CC 11-50 – 50% of the recommended dose or the usual dose every 2 days; patients on hemodialysis – 1 dose after each dialysis.